COVID-19 Antibody Levels After Vaccines

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

71 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-06-09

Study Completion Date

2022-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will measure the levels of nasal mucosal Immunoglobulin A (IgA) and blood serum IgA up to one year after COVID vaccination, as well as examining what factors might affect antibody levels in the nose. This will be done through nasal epithelial lining fluid collection and standard venipuncture.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Host Immune Response to Novel RNA COVID-19 Vaccination

NCT04784689

COVID-19 Vaccine Cancer

COMPLETED

T Cells Response to SARS COV 2 Peptides

NCT04573348

Covid19 Corona Virus Infection

UNKNOWN

Immune Response to the COVID-19 Vaccine

NCT04936997

Covid19 Cancer Malignancy +1 more

COMPLETED EARLY_PHASE1

Humoral and Cellular Immune Response to COVID-19 Vaccines in Immunocompromised and Healthy Individuals

NCT04858607

Covid19 Immunosuppression

COMPLETED

Antibodies Production After Covid-19 Vaccination Among Patients With Medical History of Cancer and Anti-CD-20 Treatment

NCT04779996

Covid19 Cancer HIV Infections

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Based on data demonstrating that SARS-CoV-2 infections results in virus-specific nasal IgA levels even in patients with mild infections and no/low serum antibody titers, we hypothesize that COVID vaccinations result in robust nasal IgA levels. Since previous data indicate that SARS-CoV2 specific IgA were transiently present following community-acquired infections, we will follow vaccine-induced nasal IgA levels over time (6-12 months). Our specific aims are as following:

Aim 1: Determine COVID vaccine specific immunoglobulin levels and immune mediator profiles in the nasal mucosa pre- and 14 days post second dose of COVID vaccine.

Aim 2: Determine COVID specific immunoglobulin levels and immune mediator profiles at 3, 6, and 12 months following complete vaccination.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vaccine Preventable Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

COVID-19 Vaccination

Receipt of full COVID-19 vaccination

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Individuals at least 18 years of age who have or plan to receive a COVID-19 vaccination
* Able to be seen at UNC Chapel Hill's main campus up to 5 times in the next year